Premium
Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone‐binding globulin levels in premenopausal women
Author(s) -
STEGEMAN B. H.,
RAPS M.,
HELMERHORST F. M.,
VOS H. L.,
van VLIET H. A. A. M.,
ROSENDAAL F. R.,
van HYLCKAMA VLIEG A.
Publication year - 2013
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.12054
Subject(s) - sex hormone binding globulin , desogestrel , ethinylestradiol , medicine , pill , endocrinology , combined oral contraceptives , estrogen , hormone , gestodene , gynecology , population , physiology , family planning , androgen , pharmacology , research methodology , environmental health
The effect of a combined oral contraceptive (COC) on sex hormone binding globulin (SHBG) levels may be an indicator for venous thrombosis risk of the COC involved [12]. SHBG is a plasma glycoprotein primarily produced in hepatocytes that binds the sex steroid hormones testosterone and 17beta-estradiol but not ethinylestradiol. Users of COC containing a third generation progestagen have higher SHBG levels than second generation progestagen users [12] reflecting the difference in venous thrombosis risk. (c) 2012 International Society on Thrombosis and Haemostasis.